Switch theme
Sign up to access all valuation multiples
Optomed PLC is a Finnish medical technology company and a manufacturer of handheld fundus cameras and screening software. The company operates in two business segments which are Devices and Software. Devices segment develops, commercializes, and manufactures easy-to-use and affordable handheld fundus cameras, that are suitable for any clinic for screening of various eye diseases, such as diabetic retinopathy, glaucoma, and AMD. The Software segment develops and commercializes screening software for diabetic retinopathy and cancer screening for healthcare organizations. The company operates in Finland, China, and other countries.
2004
115
LTM Revenue $18.3M
LTM EBITDA -$3.1M
$83.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Optomed has a last 12-month revenue (LTM) of $18.3M and a last 12-month EBITDA of -$3.1M.
In the most recent fiscal year, Optomed achieved revenue of $16.9M and an EBITDA of -$3.2M.
Optomed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Optomed valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $18.3M | XXX | $16.9M | XXX | XXX | XXX |
| Gross Profit | $12.1M | XXX | $10.9M | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | -$3.1M | XXX | -$3.2M | XXX | XXX | XXX |
| EBITDA Margin | -17% | XXX | -19% | XXX | XXX | XXX |
| EBIT | -$6.1M | XXX | -$6.7M | XXX | XXX | XXX |
| EBIT Margin | -33% | XXX | -40% | XXX | XXX | XXX |
| Net Profit | -$5.6M | XXX | -$6.1M | XXX | XXX | XXX |
| Net Margin | -31% | XXX | -36% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Optomed's stock price is EUR 4 (or $5).
Optomed has current market cap of EUR 80.8M (or $90.8M), and EV of EUR 74.6M (or $83.8M).
See Optomed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $83.8M | $90.8M | XXX | XXX | XXX | XXX | $-0.30 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Optomed has market cap of $90.8M and EV of $83.8M.
Optomed's trades at 5.0x EV/Revenue multiple, and -26.1x EV/EBITDA.
Equity research analysts estimate Optomed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Optomed has a P/E ratio of -16.1x.
See valuation multiples for Optomed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $90.8M | XXX | $90.8M | XXX | XXX | XXX |
| EV (current) | $83.8M | XXX | $83.8M | XXX | XXX | XXX |
| EV/Revenue | 4.6x | XXX | 5.0x | XXX | XXX | XXX |
| EV/EBITDA | -26.6x | XXX | -26.1x | XXX | XXX | XXX |
| EV/EBIT | -13.8x | XXX | -12.5x | XXX | XXX | XXX |
| EV/Gross Profit | 6.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -16.1x | XXX | -14.8x | XXX | XXX | XXX |
| EV/FCF | -12.8x | XXX | -20.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOptomed's last 12 month revenue growth is 30%
Optomed's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Optomed's rule of 40 is 16% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Optomed's rule of X is 59% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Optomed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 30% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Margin | -17% | XXX | -19% | XXX | XXX | XXX |
| EBITDA Growth | -90% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 16% | XXX | 11% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 59% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 104% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Optomed acquired XXX companies to date.
Last acquisition by Optomed was XXXXXXXX, XXXXX XXXXX XXXXXX . Optomed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Optomed founded? | Optomed was founded in 2004. |
| Where is Optomed headquartered? | Optomed is headquartered in Finland. |
| How many employees does Optomed have? | As of today, Optomed has 115 employees. |
| Is Optomed publicy listed? | Yes, Optomed is a public company listed on HEL. |
| What is the stock symbol of Optomed? | Optomed trades under OPTOMED ticker. |
| When did Optomed go public? | Optomed went public in 2019. |
| Who are competitors of Optomed? | Similar companies to Optomed include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Optomed? | Optomed's current market cap is $90.8M |
| What is the current revenue of Optomed? | Optomed's last 12 months revenue is $18.3M. |
| What is the current revenue growth of Optomed? | Optomed revenue growth (NTM/LTM) is 30%. |
| What is the current EV/Revenue multiple of Optomed? | Current revenue multiple of Optomed is 4.6x. |
| Is Optomed profitable? | Yes, Optomed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Optomed? | Optomed's last 12 months EBITDA is -$3.1M. |
| What is Optomed's EBITDA margin? | Optomed's last 12 months EBITDA margin is -17%. |
| What is the current EV/EBITDA multiple of Optomed? | Current EBITDA multiple of Optomed is -26.6x. |
| What is the current FCF of Optomed? | Optomed's last 12 months FCF is -$6.5M. |
| What is Optomed's FCF margin? | Optomed's last 12 months FCF margin is -36%. |
| What is the current EV/FCF multiple of Optomed? | Current FCF multiple of Optomed is -12.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
